Tolrestat for mild diabetic neuropathy. A 52-week, randomized, placebo-controlled trial.

@article{Giugliano1993TolrestatFM,
  title={Tolrestat for mild diabetic neuropathy. A 52-week, randomized, placebo-controlled trial.},
  author={Dario Giugliano and Raffaele Marfella and Antonio Quatraro and Nicla de Rosa and Teresa Salvatore and Domenico Cozzolino and Antonio Ceriello and Roberto Torella},
  journal={Annals of internal medicine},
  year={1993},
  volume={118 1},
  pages={7-11}
}
OBJECTIVE To evaluate the effectiveness and safety of tolrestat, an aldose-reductase inhibitor, in patients with mild diabetic autonomic and peripheral neuropathy. DESIGN Randomized, placebo-controlled, double-blind 52-week trial. SETTING University hospital clinic. PATIENTS Forty-five diabetic patients with asymptomatic autonomic neuropathy identified by at least one pathologic cardiovascular reflex test result. INTERVENTIONS All patients were given placebo during a 4-week run-in… CONTINUE READING
12 Citations
0 References
Similar Papers

Similar Papers

Loading similar papers…